Monographie - Dacarbazine

Ultimele actualizari :
29/10/2024

Dacarbazine

Formula chimica

Denumirea comerciala

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acocarb	Mexic
Celdaz	India, Peru
Dabaz	India
Dacarb	India, Peru
Dacarba	India
Dacarbaz	Turcia
Dacarbazin	Austria, Malaezia, Polonia, Ungaria
Dacarbazina	Argentina, Chilli, Columbia, Ecuador, Spania
Dacarbazine	Australia, Belgia, Canada, Danemarca, India, Iran, Irlanda, Marea Britanie, noua Zeelandă, SUA, Suedia
Dacarex	India, Peru
Dacarin	India
Dacarpalm	Peru
Dacarzine	India
Dacatic	Finlanda
Dacin	Elvetia
Dacmed	India
Daracina	Columbia
Deticene	Arabia Saudita, Franta, Grecia, Italia, Olanda, Tunisia
Detilem	Mexic
Detimedac	Columbia, Germania
DTI	Malaezia
DTIC	Australia, Austria, Marea Britanie, noua Zeelandă, SUA, Suedia
Fauldetic	Portugalia
Ifadac	Mexic
Oncocarbil	Argentina, Ecuador, Peru
Tiferomed	Mexic

Bibliografie : Dacarbazine

	tip	publicare
3	ziar	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26	ziar	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
40	ziar	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
57	ziar	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	ziar	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	ziar	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	ziar	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	ziar	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
184	ziar	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	ziar	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	ziar	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	ziar	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	ziar	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307	ziar	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	ziar	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	ziar	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
353	ziar	Lunn G, Sansone EB. Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid. Am J Hosp Pharm 1987 ; 44: 2519-2524.
492	ziar	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
860	ziar	Nelson RW, Young R, Lamnin M. Visual incompatibility of dacarbazine and heparin. Am J Hosp Pharm 1987 ; 44: 2028.
905	ziar	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1383	ziar	Stevens MFG, Peatey L. Photodegradation of solutions of the antitumour drug DTIC. J Pharm Pharmacol 1978 ; 30: 47P.
1410	ziar	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1501	ziar	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1635	ziar	El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F. Stability of dacarbazine in amber glass vials and polyvinyl chloride bags. Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107	ziar	Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration. Int J Pharm Compound 2006 ; 10: 234-236.
3266	Laborator	Lipomed Laboratories Dacarbazine solutions: In Use stability of dacarbazine lipomed® Lipomed 2011
3267	Laborator	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3540	Laborator	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3605	Laborator	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010

Mentions Légales